Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,373.1
15.9 (0.47%)

 

  • STI Straits Times Index
    3,373.1
    15.9 (0.47%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,655.7
    0.3 (0.02%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,466.5
    95.2 (0.34%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,899.9
    13.0 (0.45%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    21,620.9
    204.1 (0.95%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,403.8
    -29.7 (-0.46%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,101.4
    8.1 (0.39%)
    Index delayed 20 minutes
  • XAO XAO
    6,812.5
    31.3 (0.46%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,090.1M
  • Value: 895.3M
  • Rise: 221
  • Fall: 157
  • Unch: 460

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sinwa0.047+0.016
DISA0.002-
Accrelist0.004+0.002
Singapore-eDev0.051+0.015
Jadason^0.045+0.005
Sino Grandness0.051+0.001
SingTel3.520-
Sen Yue0.039-
Genting Sing0.935+0.010
Tritech0.029-

World Indices

World Indices
Name Last Change
Nasdaq 8,204.1 +57.6
HSI 28,466.5 +95.2
HSCEI 10,809.9 +39.6
Jakarta 6,403.8 -29.7
Nikkei 225 21,620.9 +204.1
SSE Comp 2,899.9 +13.0
Shanghai A 3,037.4 +13.6
Shanghai B 287.4 +0.1
ShenZhen A 1,616.6 +14.1
ShenZhen B 967.4 +0.6
PSE Comp 0.0
KOSPI 2,101.4 +8.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

NAVIDEA BIOPHARMACEUTICALS INC NAVIDEA BIOPHARMACEUTICALS INC
Updated on 22 Jul 2019 (End of trading day)
Last (USD): 0.581 Change: -0.009 High: 0.600 Remarks: -
Change (%): -1.61 Low: 0.555
Open 0.600 Yesterday's Close 0.59
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 188,135 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.09961 Trailing EPS (USD) e -0.01497 NAV (USD) b -0.0035
PE a - Trailing PE f - Price / NAV b -165.8571
Dividend (USD) d - Cash In Hand (USD) g 0.0091 Issued & Paid-up Shares c 18,059,000
Dividend Yield (%) d - Price / Cash In Hand g 63.791 Treasury Shares h -
Beta - 75 Daysi 1.891 R-Squared - 75 Days(%)i 4.73 Market Cap (M) 94.161
Beta - 500 Daysi 0.217 R-Squared - 500 Days (%)i 0.03 Enterprise Value (M) 93.885
Piotroski F Score 1 Exchange Code NAVB Par Value ( $ ) n.a.
52 Weeks Volatility (%) 117.02 Free Float (%) 64.5
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 19 Jun 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference NAVIDEA BIOPHARMACEUTICALS INC NYSE American 94.161 - - -165.8571 -
Industry Biotechnology NYSE American 74.167 - - 2.8165 -
Local Peer 22ND CENTURY GROUP INC NYSE American 196.272 - - 2.8113 -
Local Peer STANDARD DIVERSIFIED INC NYSE American 175.686 73.787 - - -
Local Peer PALATIN TECHNOLOGIES INC NYSE American 148.875 6.027 - 9.2702 -
Local Peer PFENEX INC NYSE American 139.762 - - 2.3903 -
Local Peer BIOTIME INC NYSE American 126.226 - 3.211 0.7751 -
Local Peer HEMISPHERX BIOPHARMA INC NYSE American 91.299 - - 64.6694 -
Local Peer SYNTHETIC BIOLOGICS INC NYSE American 65.521 - - 7.8000 -
Local Peer IBIO INC NYSE American 66.830 - - 9.6774 -
Local Peer MATINAS BIOPHARMA HOLDINGS INC NYSE American 65.300 - - 1.9608 -
Local Peer CEL-SCI CORP NYSE American 57.883 - - 60.6061 -
Local Peer INDIA GLOBALIZATION CAPITAL INC NYSE American 40.661 - - 1.2112 -
Local Peer ARMATA PHARMACEUTICALS INC NYSE American 33.369 - - - -
Other Local Peers ORAGENICS INC (NYSE American), ISORAY INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), NOVABAY PHARMACEUTICALS INC (NYSE American), NANOVIRICIDES INC (NYSE American), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American)
Global Peer AMGEN INC NASDAQ 107,281.643 12.781 13.286 9.9042 3.099
Global Peer GILEAD SCIENCES INC NASDAQ 82,536.960 15.131 14.008 3.7601 3.541
Global Peer AMGEN-T HKEx 609,936.000 9.271 9.631 7.1731 4.272
Global Peer CSL ASX 101,018.277 45.273 41.466 14.6569 1.022
Global Peer CELGENE CORP NASDAQ 63,099.612 15.596 13.298 7.7281 -
Global Peer BIOGEN INC NASDAQ 45,076.245 10.174 9.659 3.2593 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 44,585.544 21.268 20.691 9.4395 -
Global Peer ILLUMINA INC NASDAQ 43,847.160 53.084 51.524 11.0031 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,509.964 13.300 13.392 3.4421 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 27,428.670 353.465 65.871 2.8258 -
Other Global Peers AGILENT TECHNOLOGIES INC (NYSE), INCYTE CORPORATION (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), SINO BIOPHARM (HKEx), WUXI BIO (HKEx), SEATTLE GENETICS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), ARRAY BIOPHARMA INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), EXELIXIS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), MODERNA INC (NASDAQ), GENSCRIPT BIO (HKEx), Lonza (SGX), 3SBIO (HKEx), REPLIGEN CORP (NASDAQ), TILRAY INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ACCELERON PHARMA (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), NATERA INC (NASDAQ), REGENXBIO INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), HAOHAI BIOTEC (HKEx), NGM BIOPHARMACEUTICALS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), RETROPHIN INC (NASDAQ), VIVA BIOTECH (HKEx), FRONTAGE (HKEx), KURA ONCOLOGY INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ARVINAS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ASCLETIS-B (HKEx), INTELLIA THERAPEUTICS INC (NASDAQ), POLYNOVO LIMITED (ASX), MYOVANT SCIENCES LTD (NYSE), STOKE THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), OMEROS CORP (NASDAQ), MACROGENICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), TG THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), PERSONALIS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), AVROBIO INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), AVITA MEDICAL LTD (ASX), LEXICON PHARMACEUTICALS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), SYNTHORX INC (NASDAQ), CKLIFE SCIENCES (HKEx), CYTOMX THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), ESSEX BIO-TECH (HKEx), MESOBLAST LTD (ASX), KARYOPHARM THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), NEXT SCIENCE LTD (ASX), GLYCOMIMETICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), NEXTCURE INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), MEDICINOVA INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), LEE'S PHARM (HKEx), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), RESTORBIO INC (NASDAQ), MERUS B V (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), HARPOON THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), AVID BIOSERVICES INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), AGENUS INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), KADMON HLDGS INC (NYSE), SORRENTO THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), XBIOTECH INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), TELIX PHARMACEUTIC (ASX), MINERVA NEUROSCIENCES INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), KAMADA (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), GERON CORP (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), SYNLOGIC INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), DPHARMA (Bursa), RECRO PHARMA INC (NASDAQ), ATHERSYS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), COMPUGEN (NASDAQ), MANNKIND CORPORATION (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), CHIASMA INC (NASDAQ), AFFIMED N V (NASDAQ), CHIMERIX INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), ENZO BIOCHEM INC (NYSE), SOLID BIOSCIENCES INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), ARDELYX INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), BBI LIFE SCI (HKEx), DYADIC INTERNATIONAL INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), IMV INC (NASDAQ), TOCAGEN INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), SESEN BIO INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), NANTKWEST INC (NASDAQ), UNI-BIO GROUP (HKEx), AVEO PHARMACEUTICALS INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), NOVAVAX INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), INMUNE BIO INC (NASDAQ), VERASTEM INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), NEON THERAPEUTICS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), EQUILLIUM INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), TREVENA INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), SAVARA INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), PORT (SET), ALPINE IMMUNE SCIENCES INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), INFLARX N V (NASDAQ), OTONOMY INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), CURIS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), VTV THERAPEUTICS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), VERMILLION INC (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), ORGENESIS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), COHBAR INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), ARAVIVE INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), AQUINOX PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), REGENT PACIFIC (HKEx), CT ENTERPRISE (HKEx), IMMUTEP LTD (ASX), OPIANT PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ORTHOCELL LIMITED (ASX), VACCINEX INC (NASDAQ), PHYLOGICA LIMITED (ASX), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), IMUGENE LIMITED (ASX), ZAFGEN INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), EVOGENE LTD (NASDAQ), ZELDA THERAPEUTICS LTD (ASX), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CONTRAFECT CORP (NASDAQ), BIOTRON (ASX), INVEX THERAPEUTICS LTD NPV (ASX), SENESTECH INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), RHINOMED LIMITED (ASX), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), SOPHIRIS BIO INC (NASDAQ), EXTRAWELL PHAR (HKEx), BIONANO GENOMICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), MEMPHASYS LTD (ASX), AETERNA ZENTARIS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), BIOSINO BIO-TEC (HKEx), AEVI GENOMIC MEDIC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), AZURRX BIOPHARMA INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), SOLIGENIX INC (NASDAQ), ADALTA LTD (ASX), HEAT BIOLOGICS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), BIOCEPT INC (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), CO DIAGNOSTICS INC (NASDAQ), HISTOGENICS CORP (NASDAQ), PATRYS LIMITED (ASX), PRECIPIO INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), CLEVELAND BIOLABS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), VICAL INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), ANTEO DIAGNOSTICS LIMITED (ASX), BIONOMICS LTD (ASX), OHR PHARMACEUTICAL INC (NASDAQ), IMMURON LIMITED (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), ONCONOVA THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), ATYR PHARMA INC (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), GENETIC TECHNOLOGIES (ASX), REGENEUS LTD (ASX), DIFFUSION PHARMACEUTICALS INC (NASDAQ), CELLMID LIMITED (ASX), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), TROVAGENE INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), VAXART INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADR EA REPR 150 ORD(POST SPLIT) (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), Suntar Eco-City^ (SGX), ANATARA LIFESCIENCES LTD (ASX), HOLISTA COLLTECH LIMITED (ASX), BIOXYNE LIMITED (ASX), ADVAXIS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADR EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), PHIO PHARMACEUTICALS CORP (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), QT Vascular (SGX), PROTEON THERAPEUTICS INC (NASDAQ), HAO WEN HLDGS (HKEx), LIVING CELL TECHNOLOGIES (ASX), ACTINOGEN MEDICAL LTD (ASX), MGRC (Bursa), MEGASUN (Bursa), NEURALSTEM INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), OPGEN INC (NASDAQ), CCP TECHNOLOGIES LTD (ASX), CYTORI THERAPEUTICS INC (NASDAQ), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), XENETIC BIOSCIENCES INC (NASDAQ), NOVITA HEALTHCARE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), MEDIBIO LIMITED (ASX), NANOLLOSE LTD (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), FACTOR THERAPEUTICS LIMITED (ASX), BPH ENERGY LIMITED (ASX), SINOVAC BIOTECH (NASDAQ), ALCHEMIA LIMITED (ASX), GENERA BIOSYSTEMS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.089
-13.36 %
10 Days --0.002
-0.26 %
20 Days --0.117
-16.71 %
Medium Term Return 3 Months --2.439
-80.78 %
6 Months --1.829
-75.91 %
1 Year --3.285
-84.98 %
Long Term Return 2 Years --8.557
-93.65 %
3 Years --9.944
-94.48 %
5 Years --25.820
-97.80 %
Annualised Return Annualised --
-53.39 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.540 - 7.388 Change From 1 Year Low +0.041 % Change From 1 Year Low (%) +7.50
Change From 1 Year High -6.808 % Change From 1 Year High (%) -92.14
2 Years Range 0.540 - 13.600 Change From 2 Years Low +0.041 % Change From 2 Years Low (%) +7.50
Change From 2 Years High -13.020 % Change From 2 Years High (%) -95.73
5 Years Range 0.540 - 49.900 Change From 5 Years Low +0.041 % Change From 5 Years Low (%) +7.50
Change From 5 Years High -49.319 % Change From 5 Years High (%) -98.84
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Historical Price Data

Date Open High Low Close Volume VWAP
22 Jul 2019 0.600 0.600 0.555 0.581 188,135 -
19 Jul 2019 0.580 0.610 0.580 0.590 152,182 -
18 Jul 2019 0.653 0.653 0.580 0.580 215,288 -
17 Jul 2019 0.680 0.690 0.642 0.642 152,920 -
16 Jul 2019 0.680 0.680 0.650 0.670 181,529 -
15 Jul 2019 0.680 0.750 0.671 0.682 309,716 -
12 Jul 2019 0.670 0.740 0.640 0.705 686,321 -
11 Jul 2019 0.780 0.900 0.670 0.675 6,114,799 -
10 Jul 2019 0.580 0.610 0.580 0.602 160,340 -
09 Jul 2019 0.591 0.598 0.580 0.582 34,613 -
08 Jul 2019 0.593 0.598 0.572 0.580 133,972 -
05 Jul 2019 0.610 0.620 0.591 0.598 134,799 -
03 Jul 2019 0.619 0.645 0.591 0.591 62,923 -
02 Jul 2019 0.638 0.638 0.600 0.610 90,029 -
01 Jul 2019 0.638 0.650 0.602 0.625 130,659 -
28 Jun 2019 0.680 0.680 0.600 0.631 211,216 -
27 Jun 2019 0.594 0.670 0.540 0.665 877,833 -
26 Jun 2019 0.660 0.661 0.600 0.615 734,637 -
25 Jun 2019 0.749 0.749 0.670 0.697 673,360 -
24 Jun 2019 0.720 0.790 0.660 0.743 4,418,920 -
21 Jun 2019 0.710 0.739 0.685 0.689 734,181 -
20 Jun 2019 0.709 0.735 0.686 0.710 390,633 -
Summary
Current 2 Weeks
(09 Jul 2019 to 22 Jul 2019)
0.591 0.900 0.555 0.581 8,195,843 -
Previous 2 Weeks
(24 Jun 2019 to 08 Jul 2019)
0.720 0.900 0.555 0.580 7,468,348 -
4 Weeks from
(24 May 2019 to 21 Jun 2019)
1.360 1.415 0.555 0.689 8,065,453 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.